Enhanced protection against HSV lethal challenges in mice by immunization with a combined HSV-1 glycoprotein B:H:L gene DNAs

Chul, Soung; Kim, Young Sik; Cho, Jae Kyung; Cho, Jun; Kim, Su Yung; Kang, Hye Won; Cho, Myung Hwan; Lee, Hyung Hoan

doi:10.1016/s0168-1702(02)00037-0

Cited by 8 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CTL assay was performed as described earlier [17]. Briefly, mixed splenocytes from 10 mice in each group were stimulated with the MEAP protein (10 μg/ml) in 1 ml of RPMI 1640 medium with 10% FCS in 24-well microplates at 37°C for 6 days.…”

Section: Methodsmentioning

confidence: 99%

“…To ensure infection, a virus application was repeated 1 h later. The infected mice were examined daily for vaginal inflammation, neurological illness, and death, and then were scored in steps 1-5 depending on the severity of disease as described by the reported papers [17,18]. Vaginal washings were collected on days 1, 2, 3, and 4 post inoculation after the intravaginal challenge with pipetting 100 μl of PBS into the vaginal cavity.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice

Xingsheng

Xie

Liao

et al. 2011

Virol J

View full text Add to dashboard Cite

BackgroundHuman herpes simplex virus (HSV) 1 and 2 causes oral, ocular, or genital infections, which remains a significant health problem worldwide. HSV-1 and -2 infections in humans range from localized skin infections of the oral, ocular, and genital regions to severe and often disseminated infections in immunocompromised hosts. Epitope based vaccination is a promising mean to achieve protective immunity and to avoid infections with Human herpes simplex virus type 2 (HSV-2).MethodsThe twelve selected epitopes, six B cell epitopes from different glycoprotein of HSV-2 (amino acid residues 466-473 (EQDRKPRN) from envelope glycoprotein B, 216-223 (GRTDRPSA) from C, 6-18 (DPSLKMADPNRFR) from D, 483-491 (DPPERPDSP) from E, 572-579 (EPPDDDDS) from G and 286-295 (CRRRYRRPRG) from I glycoprotein of HSV-2), four CD4+ T cell epitopes (amino acid residues 21-28 (NLPVLDQL) from D, 162-177 (KDVTVSQVWFGHRYSQ) from B, 205-224 (KAYQQGVTVDSIGMLPRFIP) from D and 245-259 (KPPYTSTLLPPELSD) from D) and two CD8+ T cell epitopes (amino acid residues 10-20 (KMADPNRFRGK) from D and 268-276 (ALLEDPAGT) from D), are responsible for the elicitation of the neutralizing antibodies and cytotoxic T lymphocytes (CTLs) that impart protective immunity to the host. In this study, all above epitopes were inserted into the extracellular fragment (amino acid residues 1-290) of HSV-2 glycoprotein D to construct multi-epitope assembly peptides (MEAPs) by replacing some non-epitope amino acid sequences. The epitope independency of the MEAPs was predicted by three-dimensional software algorithms. The gene of the selected MEAP was expressed in E.coli BL21(DE3), and its protective efficacy against HSV-2 infection was assessed in BALB/c mice.ResultsThe MEAP, with each inserted epitopes independently displayed on the molecule surface, was selected as candidate proteins. The results showed that the MEAP was highly immunogenic and could elicit high titer neutralizing antibodies and cell-mediated immune responses.ConclusionsThe MEAP provided complete protection against infection with HSV-2 in mice, which indicates that it might be a potential candidate vaccine against HSV-2.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice

Xingsheng

Xie

Liao

et al. 2011

Virol J

View full text Add to dashboard Cite

show abstract

“…The generation of a successful vaccine against HSV-1 is a challenge due to the virus-encoded immune countermeasures directed at the innate and adaptive immune systems, the establishment of latency in neurons that allows the virus to "hide" from probing lymphocytes and circulating antibodies and the subclinical reactivation nature of the virus in a large reservoir of infected individuals. Experimental vaccines against HSV-1 consists of heat-killed virus, live-attenuated virus, virus-encoded protein subunits (typically glycoproteins) and subunit cocktails [14][15][16][17][18][19][20][21][22][23][24]. These vaccines have been deemed successful by the reporting investigative team based on providing sterile immunity, the induction of a robust immune (B and/or T cell) response and in some instances, reduction of tissue inflammation.…”

Section: Introductionmentioning

confidence: 99%

The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time

2021

View full text Add to dashboard Cite

Vaccines to viral pathogens in experimental animal models are often deemed successful if immunization enhances resistance of the host to virus challenge as measured by cumulative survival, reduction in virus replication and spread and/or lessen or eliminate overt tissue pathology. Furthermore, the duration of the protective response against challenge is another important consideration that drives a vaccination regimen. In the current study, we assessed the durability of two related vaccines, 0∆NLS and 0∆RING, against ocular herpes simplex virus type 1 (HSV-1) challenge in mice thirty days (short-term) and one year (long-term) following the vaccine boost. The short-term vaccine efficacy study found the 0∆RING vaccine to be nearly equivalent to the 0∆NLS vaccine in comparison to vehicle-vaccinated mice in terms of controlling virus replication and preserving the visual axis. By comparison, the long-term assessment of the two vaccines found notable differences and less efficacy overall as noted below. Specifically, the results show that in comparison to vehicle-vaccinated mice, the 0∆NLS and 0∆RING vaccinated groups were more resistant in terms of survival and virus shedding following ocular challenge. Moreover, 0∆NLS vaccinated mice also possessed significantly less infectious virus in the peripheral and central nervous systems but not the cornea compared to mice vaccinated with vehicle or 0∆RING which had similar levels. However, all vaccinated groups showed similar levels of blood and lymphatic vessel genesis into the central cornea 30 days post infection. Likewise, corneal opacity was also similar among all groups of vaccinated mice following infection. Functionally, the blink response and visual acuity were 25–50% lower in vaccinated mice 30 days post infection compared to measurements taken prior to infection. The results demonstrate a dichotomy between resistance to infection and functional performance of the visual axis that collectively show an overall loss in vaccine efficacy long-term in comparison to short-term studies in a conventional prime-boost protocol.

show abstract

Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice

Ghaemi

Soleimanjahi

Bamdad

et al. 2007

Comparative Immunology, Microbiology and Infectious Diseases

View full text Add to dashboard Cite

Enhanced protection against HSV lethal challenges in mice by immunization with a combined HSV-1 glycoprotein B:H:L gene DNAs

Cited by 8 publications

References 29 publications

Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice

Design and evaluation of a multi-epitope assembly Peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice

The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time

Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice

Contact Info

Product

Resources

About